MCX
METAL & ENERGY
Trade with Trust

MCX/SEC/2639

February 10, 2026

Listing Department
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai 400001

Scrip code: 534091, Scrip ID: MCX

Subject: Intimation on publication of newspaper advertisements

Dear Sir/Madam,

Please find enclosed copy of the newspaper advertisement published in 'Times of India', 'The Economic Times', 'Mint' and 'Business Standard' on Tuesday, January 10, 2026, *inter alia*, inviting applications for the key positions of Executive Directors, pursuant to SEBI Circular dated December 12, 2025.

The same will also be available on the website of the Company at www.mcxindia.com

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Multi Commodity Exchange of India Limited

Manisha Thakur
Company Secretary

Multi Commodity Exchange of India Limited * Mumbai *

Encl: as above

MULTI COMMODITY EXCHANGE OF INDIA LTD.
EXCHANGE SQUARE, SUREN ROAD, ANDHERI (EAST), MUMBAI 400 093, INDIA. TEL: +91-22-6731 8888, FAX: +91-22-66494151, www.mcxindia.com
CIN: L51909MH2002PLC135594, info@mcxindia.com

Wangchuk getting proper med care in custody: Govt

Opposes Review Of Activist's Detention In SC

Amit Anand.Choudhary
@timesofindia.com


There is 'nothing' in Ladakh to care for Wanchuk's health, ASG told SC

New Delhi: Centre on Monday expressed its disinclination towards review of detention of climate activist Sonam Wangchuk on medical grounds saying that he was getting proper treatment in detention by AIIMS Jodhpur and there is "nothing" in Ladakh to care for his health. Though the govt is yet to take a final decision, the response came when SC asked about its suggestion given on the last hearing on the relook.

When additional solicitor general K M Nataraj pleaded a bench of Justices Aravind Kumar and P B Varale to adjourn the hearing, the court asked him whether there was any progress on its suggestion made on the last hearing regarding relook of detention. "Any progress? We made a suggestion on the last date," the bench asked.

The ASG said that he would submit on the issue when he argued the case and the final decision had not been taken. He told the court that the activist was getting the best of treatment.

When the court told ASG that it had made the suggestion because of his medical issues and the govt was also aware about it, the ASG said that the activist was being taken care of by AIIMS Jodhpur and there was nothing in Ladakh to care for his health.

"There are issues, and it is not like you are denying it, and he is also making a complaint of health issues. The doctor says yes, it is there, and now treatment is being provided. Admittedly, the health issue is there..," the bench observed. Observing that the medical condition of Wangchuk, who has been in detention for more than four months, was not very good, SC had last week asked the Centre to rethink/relook its decision to continue to keep him in custody.

The activist is presently lodged in Jodhpur jail. Wangchuk was detained on Sept 26, 2025 under National Security Act (NSA) following protests in Leh over demands of statehood and Sixth Schedule status for the Union Territory of Ladakh.

SC is hearing the plea moved by Wangchuk's wife Gitanjali Angmo against his preventive detention.

SC upholds HC order prohibiting animal sacrifice on TN hilltop

New Delhi: The Supreme Court on Monday refused to interfere with Madras high court's decision prohibiting animal sacrifice and granting Muslim devotees limited rights to pray on the Thiruparankundram hills in Tamil Nadu's Madurai.

A bench of Justices Aravind Kumar and P B Varale said that the order passed by HC on Oct 10 was balanced and refused to entertain an appeal against it. The HC had held that any animal sacrifice and the cooking, carrying or serving of any non-vegetarian food cannot be permitted in the Nellithoppu area until a decision is rendered by a competent civil court with regard to the customary practice of animal sacrifice on the hillock.

SC said, "It seems to be a very balanced order...We do not propose to interfere with the order. Without expressing any opinion on the rights of the parties, the impugned order stands upheld." TNN

HC judges cannot assume domain experts' role: SC

Dhananjay.Mahapatra
@timesofindia.com

New Delhi: Supreme Court on Monday cautioned constitutional court judges against assuming the role of domain experts and suggesting remedial steps and said it would be dangerous if they deviate from their primary duty to decide disputes as neutral umpires after considering rival submissions.

The remark came from a bench of Chief Justice Surya Kant, Justices Joymalya Bagchi and N V Anjaria on a petition filed by Jharkhand Public Service Commission (JPSC) challenging Jharkhand HC's decision to direct deletion of two questions and award of one mark to either of two options to a question attempted by candidates appearing in a preliminary test for recruitment of judicial officers.

CJI Kant said, "Should a constitutional court assume the role of super-examiner just because the test was for recruitment of judicial officers and the question related to law? It will be very dangerous if HC judges assume the role of domain experts."

'DANGEROUS IF THEY INTERFERE IN EXAMS'

"Tomorrow a judge may have knowledge of biochemistry. Should he interfere in examination question papers and answer keys relating to recruitments in the field of biochemistry? HC judges must leave these issues to domain experts," the CJI said. The bench said HC, on the administrative side, had framed the questions in consultation with JPSC.

"The power of reappreciation/reconsideration of answer sheets must be uniform for all examinations and not only for judicial service tests, HCs cannot be super-examiners," it said.

"If that is so, it is necessary that HC, while exercising the power of judicial review, should have referred the issue to the administrative side of HC for constituting an expert committee to revisit the answer sheets and answer keys," the bench said.

The bench asked HC to set up an expert committee that will include subject experts, including those from the fields of law and English, to reevaluate the answer keys and answer sheets.

When the counsel sought an early resolution of the controversy, the bench asked high court to resolve it within two weeks and send a report to JPSC.

Raj stalker who stabbed siblings to death gets life in jail, ₹60k fine

Jaipur: An additional sessions court in Jaipur has sentenced a man to life imprisonment for stabbing a 16-year-old girl, whom he had been harassing for marriage, and her brother nearly four years ago. The court ruled that no leniency could be shown to the accused, Gulshan, and also imposed a fine of Rs 60,000.

The siblings' father had filed an FIR at Sadar police station in Jaipur on May 5, 2022. According to the prosecution, the accused lived near the house of the deceased siblings. He had been harassing the complainant's minor daughter to force her into marrying him. Three days before the crime, Gulshan had even threatened to kill her, if she did not agree.

On the day of murder, accused arrived and again started threatening the girl. An argument started between him and siblings, following which accused stabbed them. TNN

Ajanta Eyes 2k-cr Fundraise for Burger King Franchisee

Pharma co likely to opt for promoter-level borrowing and debt to fund the deal

Shilpy Sinha

Diversification Drive

WHY THE FUND RAISE

- **To back** the acquisition of a controlling interest in Restaurant Brands Asia
- **PE firm** Everstone Capital is preparing to exit its entire 11.26% stake

MONEY TO BE RAISED VIA

- Promoter-level borrowing
- Debt at operating company

Mumbai: Ajanta Pharma's promoters are exploring financing options of up to ₹2,000 crore to fund the acquisition of a controlling stake in Restaurant Brands Asia, the India and Indonesia franchisee of Burger King, in a transaction that would mark the drugmaker's diversification into the fast-growing quick service restaurant sector.

The promoter group is looking to raise about ₹2,000 crore through a combination of promoter-level borrowing and debt at the operating company, according to people familiar with the discussions.

The financing structure is still being finalised and no lender has been formally appointed, the people said.

Barclays and Standard Chartered are among banks that have been sounded out for the funding, though talks remain at a preliminary stage. The individual banks and the companies did not respond to **ET**'s requests for comment. The fundraise is aimed at backing the acquisition of a controlling interest in Restaurant Brands Asia, where private equity firm Everstone Capital is preparing to exit its entire 11.26% stake. Restaurant Brands Asia has a market capitalisation of roughly ₹3,800 cr.

"Lenders are assessing leverage, cash-flow visibility and collateral structures before committing to the deal," said a source.

Earlier this month, Restaurant Brands Asia said it had entered into a definitive agreement with Inspira Global Group, under which the latter will infuse ₹900 crore through a preferential equity allotment and a further ₹700 crore via warrants, both priced at ₹70 a share.

Following completion of the transaction and acquisition of existing promoter shares, Inspira Global expects its total holding to rise to about 35%, triggering a mandatory open offer to public shareholders.

The acquisition is executed through Lenexis Foodworks Pvt, the food and beverage arm of Inspira Global. Lenexis operates the Chinese Wok brand and is promoted by Aayush Madhusudan Agrawal and Madhusudan Agrawal, members of the Ajanta Pharma promoter family. Inspira Global has interests spanning food and beverage, real estate, pharma, luxury home products and clean energy.

Restaurant Brands Asia, formerly Burger King India, holds master franchise rights for Burger King in India and operates Burger King and Popeyes restaurants in Indonesia. The financing comes as Ajanta Pharma's promoter group already carries pledged shares.

Marico to Buy 75% in Vietnam's Skinetiq

Mumbai: Marico on Monday said it will acquire 75% equity stake in Vietnamese direct to consumer beauty and personal care company Skinetiq Joint Stock Company, based on an equity valuation of ₹350 crore.

The company's subsidiary Marico South-East Asia Corporation will acquire 75% of Skinetiq's total shares from its existing shareholders and said it can acquire Skinetiq's remaining shares after FY28, given the achievement of requisite milestones.— **Our Bureau**

Tata Steel hunts for iron ore as legacy mines' leases to end

Firm meets 100% of iron ore needs from six legacy mines, but leases start expiring from 2030

POST-2030 PLAYBOOK

Easing aircraft supply puts Akasa back on growth path

Akasa has restarted pilot hiring after an 18-month pause, initially focusing on experienced first officers

Feb 10 ▾ | Mint | Mumbai ▾

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANJALI SINGH
Mumbai, 10 February

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulation.

They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers — particularly China — are moving rapidly up the value chain.

Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India — The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, GV Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas.

Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive–style PRIP scheme and plans to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India had underestimated China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearances, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

ILLUSTRATION: AJAYA MOHANTY

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

The panel stressed that "fast follower" drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, specialty generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry–academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

APPOINTMENTS